Peptide LibrarySuprefort
Also known as: Pancreas bioregulator
Suprefort (also called Pancreas bioregulator) is a khavinson bioregulator. Suprefort is a peptide preparation derived from pancreatic tissue and marketed in the Khavinson tradition as a pancreatic bioregulator.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- Not established (small tripeptide)
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Hepatocytes (proposed)
Vendor price snapshot
None of these listings has a price per mg to compare. From public vendor listings; confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 1
- Listed offers
- 2
- Price per mg
- —
Research summary
Peptide preparation derived from pancreatic tissue and marketed as a pancreatic bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Suprefort itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Suprefort profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Suprefort dosage: no established human dose
Suprefort has no established human dosage. It is sold as capsules described as a pancreas peptide bioregulator, a tissue-derived peptide complex. No trial of it is registered on ClinicalTrials.gov, and no study of Suprefort itself is indexed in PubMed. The nearest human evidence is for pancragen, a different synthetic pancreatic peptide, and that abstract gives no dose.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Suprefort is marketed as a peptide complex from pancreatic tissue, sold as an oral capsule. No human, animal or cell study of this product is indexed in PubMed. The related human study used pancragen (Lys-Glu-Asp-Trp), a synthetic tetrapeptide, and states no dose. Nothing here establishes a human dose, route or interval for Suprefort.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Related pancreatic peptide (analog) — pancragen in older people with and without type 2 diabetes (2011)Clinical trial · Clinical study of a different compound (analog evidence)Studied an analog, not Suprefort itself | Older adults: 30 healthy and 33 with type 2 diabetes | Not stated in the indexed abstract | Not stated in the indexed abstract | — | — | In the diabetes group, pancragen lowered fasting glucose and glucose during a glucose tolerance test, and reduced insulin and the insulin-resistance index | Prospects of using pancragen for correction of metabolic disorders in elderly people. Bull Exp Biol Med. 2011. |
Where sources disagree
- Daily capsule protocols for Suprefort are published by sellers. No registered trial or indexed study reports a dose for it.
- Suprefort (a tissue-derived complex) and pancragen (a synthetic tetrapeptide) are different products. The pancragen profile covers pancragen itself.
- Suprefort is not a diabetes treatment.
Sequence & molecular data
| Half-life | Not established (small tripeptide) |
|---|---|
| Appearance | White lyophilized powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Suprefort is a peptide preparation derived from pancreatic tissue and marketed in the Khavinson tradition as a pancreatic bioregulator. It is a complex of low-molecular-weight peptides rather than a single defined molecule, so no specific sequence, receptor or pathway can be attributed to it, and it is distinct in that respect from Pancragen, the synthetic tetrapeptide associated with the same tissue. The proposed mechanism is the series hypothesis of tissue-derived peptides influencing transcription in the corresponding tissue. No controlled human efficacy trials of this preparation have been published.
Origin
Peptide preparation from pancreatic tissue (per its description).
Targets
Studies
- Peptides and Ageing (class-level)
- Tissue-specific effects of peptides (class-level)
- Peptide bioregulation of aging: results and prospects (class-level evidence)
- Mechanisms underlying geroprotective effects of peptides (class-level evidence)
- Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b (class-level evidence)
Regulatory & research status
Suprefort is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Suprefort side effects
Suprefort has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Not characterized
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Suprefort: frequently asked questions
What is Suprefort?
Peptide preparation derived from pancreatic tissue and marketed as a pancreatic bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Suprefort itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators.
How does Suprefort work?
Suprefort is a peptide preparation derived from pancreatic tissue and marketed in the Khavinson tradition as a pancreatic bioregulator. It is a complex of low-molecular-weight peptides rather than a single defined molecule, so no specific sequence, receptor or pathway can be attributed to it, and it is distinct in that respect from Pancragen, the synthetic tetrapeptide associated with the same tissue.
Is Suprefort FDA approved?
No. Suprefort is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Suprefort?
Reported half-life for Suprefort is Not established (small tripeptide). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What peptides are similar to Suprefort?
Compounds most often compared with Suprefort include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Class-level evidence — Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett, 2002External reference
- Class-level evidence — Tissue-specific effects of peptides. Bull Exp Biol Med, 2001External reference
- Class-level evidence — Peptide bioregulation of aging: results and prospects — Biogerontology, 2010External reference
- Class-level evidence — Mechanisms underlying geroprotective effects of peptides — Bull Exp Biol Med, 2002External reference
- Class-level evidence — Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b — Mol Biol (Mosk), 2019External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 4
This Suprefort profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Suprefort research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →